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Reduction in Migratory Phenotype 
in a Metastasized Breast Cancer Cell 
Line via Downregulation of S100A4 
and GRM3
Andy Chen1, Luqi Wang2,3, Bai-Yan Li3, Jesse Sherman2, Jong E. Ryu4, Kazunori Hamamura5, 
Yunlong Liu6, Harikrishna Nakshatri7 & Hiroki Yokota2
To investigate phenotypic and genotypic alterations before and after bone metastasis, we conducted 
genome-wide mRNA profiling and DNA exon sequencing of two cell lines (TMD and BMD) derived from 
a mouse xenograft model. TMD cells were harvested from the mammary fat pad after transfecting 
MDA-MB-231 breast cancer cells, while BMD cells were isolated from the metastasized bone. Compared 
to BMD cells, TMD cells exhibited higher cellular motility. In contrast, BMD cells formed a spheroid 
with a smoother and more circular surface when co-cultured with osteoblasts. In characterizing mRNA 
expression using principal component analysis, S100 calcium-binding protein A4 (S100A4) was aligned 
to a principal axis associated with metastasis. Partial silencing of S100A4 suppressed migratory 
capabilities of TMD cells, while Paclitaxel decreased the S100A4 level and reduced TMD’s cellular 
motility. DNA mutation analysis revealed that the glutamate metabotropic receptor 3 (GRM3) gene 
gained a premature stop codon in BMD cells, and silencing GRM3 in TMD cells altered their spheroid 
shape closer to that of BMD cells. Collectively, this study demonstrates that metastasized cells are less 
migratory due in part to the post-metastatic downregulation of S100A4 and GRM3. Targeting S100A4 
and GRM3 may help prevent bone metastasis.
Tumor cells initiate their fate from non-tumor origins and continue to evolve via various transforma-
tions1, 2. While breast cancer cells originate as epithelial cells to form the primary tumor, they may acquire 
cellular motility and form a more invasive secondary tumor3. This metastatic alteration can be driven by 
epithelial-to-mesenchymal transition (EMT), in which the original epithelial nature is transformed into the 
migratory mesenchymal nature4, 5. However, many metastasized cells do not experience EMT, and the reverse 
transition, mesenchymal-to-epithelial transition, is speculated but not always confirmed6. Recent studies have 
indicated that metastasis may occur through the cooperative action of heterogeneous clusters of both epithelial 
and mesenchymal tumor cells6, 7. Since bone is the most frequent site of metastasis from breast cancer8, any phe-
notypic and genotypic differences before and after bone metastasis is critically important for determining the 
mechanism of metastasis as well as identifying diagnostic and therapeutic targets.
In this study, we focused on the differential migration and invasion abilities in two lines of breast cancer cells 
(TMD and BMD lines), which were harvested from a mouse xenograft model9, 10. In this model, MDA-MB-231 
breast cancer cells were transfected into a mouse mammary fat pad, and TMD and BMD cells were recovered 
from the transfected site and metastasized bone, respectively. Using cDNA microarrays, genome-wide mRNA 
expression profiles were determined in these cells together with the parental MDA-MB-231 cells for predicting 
the genes involved in differential cellular motility. We also conducted DNA mutation analysis, focusing on exonic 
1Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, 47907, USA. 2Department 
of Biomedical Engineering, Indiana University Purdue University Indianapolis, Indianapolis, IN, 46202, USA. 
3Department of Pharmacology, School of Pharmacy, Harbin Medical University, Harbin, 150081, China. 4Department 
of Mechanical Engineering, Indiana University Purdue University Indianapolis, Indianapolis, IN, 46202, USA. 
5Department of Pharmacology, School of Dentistry, Aichi-Gakuin University, Nagoya, Japan. 6Department of Medical 
and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA. 7Department of Surgery, 
Simon Cancer Research Center, Indiana University School of Medicine, Indianapolis, IN, 46202, USA. Correspondence 
and requests for materials should be addressed to H.Y. (email: hyokota@iupui.edu)
Received: 1 February 2017
Accepted: 4 May 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7: 3459  | DOI:10.1038/s41598-017-03811-9
mutations that were potentially involved in the migratory behaviors of BMD and TMD cells. DNA from these cell 
lines were sequenced, and DNA variants in BMD cells were identified and characterized.
To extract metastasis-linked genotypic information from genome-wide mRNA expression profiles, principal 
component analysis (PCA) was applied. PCA is a mathematical procedure that decomposes mRNA expression 
levels into an orthogonal set of principal components (PCs)11, 12. Use of three cell lines in this study provided three 
PC axes, analogous to three degrees of freedom. Our primary interest herein is the differences in two cell lines 
(TMD vs. BMD cells). We focused on the first and second PC axes and located the set of genes that were likely to 
be involved in the differential migratory and invasive behaviors in the two cell lines.
Three in vitro assays were employed to characterize phenotypic differences in migratory and invasive behaviors, 
including a 2-dimensional motility assay13, a 3-dimensional invasion assay14, and a 3-dimensional spheroid assay15. 
Furthermore, a microfluidic assay was employed to characterize cellular motility in the presence and absence of 
Paclitaxel16–18.
Results
Higher migratory and invasive behavior of TMD cells than BMD cells. In a 2-dimensional cell 
motility assay, TMD cells exhibited a significantly higher motility than BMD cells (Fig. 1A,B). Furthermore, 
TMD cells showed a greater ability of invasion than BMD cells in a 3-dimensional invasion assay (Fig. 1C,D). In 
a 3-dimensional culture for spheroid formation, TMD cells formed a larger cluster of cell aggregates than BMD 
cells (Fig. 1E,F). When these cells were co-cultured with MC3T3 osteoblast-like cells, BMD cells formed a sphe-
roid with a more circular and smoother surface than TMD cells (Fig. 1E–H).
Differential expression of S100A4 highlighted in genome-wide principal component analy-
sis. Three cell lines (MDA-MB-231 parental cells, TMD cells and BMD cells) were located in the first and 
second PC plane, which was defined by performing singular value decomposition on a matrix of genome-wide 
mRNA expression (Fig. 2A). The first PC axis positioned TMD cells between the parental cells and BMD cells, 
while the second PC axis was ~20° rotated from the metastasis axis parallel to the line connecting TMD cells 
and BMD cells. We selected the genes whose expression level had a high contribution along the metastasis axis 
(Fig. 2B,C). Of note, the values in the color-coded panels indicate the microarray-derived relative expression 
levels on a logarithmic scale (base 2). Among such genes, qPCR confirmed that the expression level of three 
genes (S100A4, SSX1, and CDH12) are significantly different in TMD cells and BMD cells (Fig. 2D). Hereafter, 
we focused on S100A4 since its mRNA and protein levels were consistently higher in TMD cells than the parental 
and BMD cells in 2- and 3-dimensional cultures (Fig. 2D,E).
Suppression of invasion behaviors of TMD cells by S100A4 siRNA. A partial silencing of S100A4 
by S100A4 siRNA reduced the mRNA and protein levels of S100A4 (Fig. 3A,B). This RNA interference reduced 
invasion capability in TMD cells and BMD cells in the 3-dimensional invasion assay (Fig. 3C). Furthermore, 
S100A4-treated TMD cells altered their phenotypic characteristics in spheroid formation (Fig. 3D). Compared 
to TMD cells treated with the non-specific siRNA, TMD cells treated with S100A4 siRNA significantly decreased 
their spheroid area as well as their surface roughness (Fig. 3E–G).
Effects of GRM3 mutation in spheroid formation. MuTect analysis of the exon sequences, compar-
ing BMD variants to the TMD reference sequence, identified 4 stop-gains (GRM3, BHMT2, REXO1L1P, and 
FCGR1A) and 21 amino acid substitutions (0.42 to 0.70 allele frequency) that occurred in BMD cells but not 
TMD cells (Table 1). The mutation in GRM3 formed a truncated protein (78 amino acids instead of 879 amino 
acids in wildtype) in BMD cells (Fig. 4A). Partial silencing of GRM3 in TMD cells using RNA interference par-
tially transformed the spheroid shape of TMD cells into that of BMD cells (Fig. 4B,C). More specifically, siRNA 
treatment significantly reduced the spheroid area and roughness of TMD cells (Fig. 4D–F). Western blot analysis 
revealed that compared to TMD cells, BMD cells had lower expression levels of S100A4, p-p38, and p-Paxillin, 
while their expression levels were higher for p-Akt, p-JNK, and β-catenin (Fig. 4G). In response to RNA interfer-
ence with GRM3 siRNA, the level of p-p38 was lowered in BMD cells.
Co-culture spheroid formation assays were also performed with TMD cells in the presence of 0.5, 5, and 20 µM 
spaglumic acid, an agonist of GRM3. The spheroid area increased by treatment with spaglumic acid, indicating a 
more migratory environment (Fig. 4H).
Involvement of integrin β, MMP9, and phosphodiesterases (PDEs). We also examined any dif-
ferential expression of integrin β and MMP9, which would potentially alter the microenvironment for cellular 
migration. Genome-wide expression analysis revealed that the mRNA levels of four members of integrin β family 
(B3, B4, B5, and B8) were significantly elevated in TMD cells (Fig. 5A,B). While the mRNA level of MMP9 was 
not of statistical significance, its activity level in cell culture medium was higher in TMD cells than BMD cells 
when 10 μM GM1489 (MMP1 inhibitor) was administered (Fig. 5C,D). Of note, the binding affinity of GM1489 
is reported to be 0.2 nM for MMP1, and 100 nM for MMP9.
To evaluate a potential linkage of GRM3 to the inactivation of cAMP signaling followed by the stimulation 
of cellular migration, we determined the mRNA levels of PDEs in the microarray data. Compared to BMD cells, 
the selected PDEs were upregulated in TMD cells (Fig. 5E). In particular, the fold increase of PDE8B in TMD 
cells was 4.66, the highest increase among all PDEs. To further evaluate the role of GRM3 in cAMP signaling, 
we determined the mRNA levels of these PDEs (1C, 4B, 5A, and 8B) in the presence of non-specific control and 
GRM3 siRNA. The qPCR result showed that a partial silencing of GRM3 significantly downregulated the mRNA 
levels of PDE8B, PDE4B, and PDE5A in TMD cells (Fig. 5F).
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Effects of Paclitaxel in motility, S100A4 expression, and behavior in a microfluidic channel. 
Paclitaxel is a popularly used drug for treatment of breast cancer. Both TMD cells and BMD cells were sensi-
tive to 10 µM Paclitaxel and reduced their motility in a 2-dimensional scratch assay (Fig. 6A,B). Furthermore, 
the protein level of S100A4 was reduced by 10 µM Paclitaxel (Fig. 6C). Using a microfluidic channel that was 
connected to a hydrodynamic syringe pump, the passing behavior of TMD cells through a tapered channel was 
evaluated (Fig. 6D). The channels were 300-µm long with an inlet (30 µm) and several different sized outlets 
(5, 10, and 15 µm). We focused on an outlet with a 5-µm diameter and determined the passing time of cells 
through the channel for TMD cells (control) and Paclitaxel-treated TMD cells (Fig. 6E,F). The results showed that 
Paclitaxel-treated TMD cells required longer passing time on average than control cells.
Figure 1. Phenotypic characterization of TMD cells and BMD cells. Of note, T = TMD cells, B = BMD cells, 
and MC = MC3T3 osteoblast-like cells. The single asterisk indicates p < 0.05. (A,B) Higher motility of TMD 
cells than BMD cells in a 2-dimensional scratch assay. (C,D) Higher invasion capability of TMD cells than 
BMD cells in a 3-dimensional invasion assay. (E) Spheroid formation of TMD and BMD cells with and without 
MC3T3 osteoblast-like cells. (F–H) Three spheroid parameters (area, roughness, and circularity, respectively) in 
TMD cells and BMD cells.
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Discussion
PCA-based characterization of two cell lines revealed that the increased motility and invasion in TMD cells, 
tumor-derived cells, than BMD cells, harvested from bone metastasis, was linked to the elevated expression 
level of S100A4 calcium-binding protein and functionality of GRM3. A partial silencing of S100A4 suppressed 
the migratory behavior of TMD cells, and it further reduced cellular motility of BMD cells. Consistent with 
their migratory and invasive abilities, the more migratory TMD cells formed larger, looser, and less organized 
spheroids, while the metastatic BMD cells formed smaller, tighter, and more organized spheroids. Silencing 
S100A4 and GRM3 genes made the TMD cells form tighter spheroids, indicating potential roles in promoting 
Figure 2. Genome-wide mRNA expression analysis of TMD cells and BMD cells. Of note, PC = principal 
component, 2D = 2-dimensional culture, and 3D = 3-dimensional spheroid culture. The double asterisks 
indicate p < 0.01. (A) Projection of three cell lines in the first/second PC array plane (PC1 and PC2). (B) 
Projection of S100 proteins and others in the PC gene plane (PC1° and PC2°). Note that the metastasis axis 
(PC2° axis) is ~20° tilted from the second PC axis (PC2 axis). (C) Representative genes whose mRNA expression 
levels are significantly different in TMD cells and BMD cells along the metastasis axis. (D) qPCR confirmation 
of mRNA expression levels of S100A4, SSX1, and CDH12 in TMD cells and BMD cells in 2-dimensional and 
3-dimensional (spheroid) cultures. (E) Elevated protein level of S100A4 in TMD cells in 2- and 3-dimensional 
cultures. Full length blots are presented in Supplementary Figure 1.
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metastasis in the bone microenvironment. A microfluidic assay with a tapered channel found that TMD cells 
passed more quickly, suggesting increased deformability. Paclitaxel treatment increased passing time in the chan-
nel, reduced S100A4, and inhibited TMD’s migratory ability. Our observation is consistent with an inhibitory role 
of Paclitaxel18 as well as a stimulatory role of S100A4 and GRM3 in cell adhesion and migration.
S100A4, a member of the S100 calcium binding protein family, was found to be a key gene in the migratory 
behavior of TMD cells that contributes to bone metastasis. The S100 protein family is composed of over 20 mem-
bers in humans19, and many S100 proteins are known to be involved in tumor growth and metastasis20. In breast 
cancer, many S100 proteins are overexpressed. In particular, it is reported that S100A1 and S100A7 are linked 
to tumor growth, while S100A4 and S100A8 are linked to metastasis. S100A4 is active in the leading edge of 
migrating cancer cells20. Among the selected genes located at the extreme edges of the principal component plane, 
the mRNA level of S100A4 in TMD cells was significantly higher than not only BMD cells but also the parental 
Figure 3. Effects of S100A4 siRNA in invasion capability and spheroid formation in TMD cells. Of note, 
NC = non-specific control siRNA, 2D = 2-dimensional culture, and 3D = 3-dimensional spheroid culture. The 
single and double asterisks indicate p < 0.05 and p < 0.01, respectively. (A,B) Reduction of S100A4 mRNA and 
protein levels by S100A4 siRNA, respectively. Full length blots are presented in Supplementary Figure 2.  
(C) Reduction in invasion capability by S100A4 siRNA in TMD cells and BMD cells. (D) Representative 
images of spheroids by TMD cells, S100A4 siRNA treated TMD cells, and BMD cells in the presence of MC3T3 
osteoblast-like cells. (E–G) BMD-like transformation of three spheroid parameters (area, roughness, and 
circularity, respectively) by S100A4 siRNA.
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cells. While the mRNA levels of SSX1 and CDH12 in TMD cells were smaller than in BMD cells, they were not 
significantly different from those of the parental cells. It is reported that S100A4 neutralizing antibody suppresses 
spontaneous tumor progression21. In this study, silencing S100A4 decreased the migratory character of TMD 
cells, suggesting that S100A4 is involved in promoting metastasis by the pre-metastatic TMD cells. Principal com-
ponent analysis identified S100A4 as a metastasis-related gene, and further studies may explore its interactions 
with other genes on this bone metastasis axis.
GRM3, a glutamate receptor, has been considered a potential target for treating psychiatric disorders via mod-
ulating the response to glutamate as a neurotransmitter22. In this study, GRM3 was found to contribute to the 
migratory behavior of TMD cells. In our DNA sequencing analysis, GRM3 mutation in BMD cells changed the 
glutamate residue into a stop codon in the 78th amino acids. The truncated GRM3 does not include glutamate 
binding sites or transmembrane domains, and it is apparently incapable of functioning as a G protein-coupled 
receptor. GRM3 is reported frequently mutated in melanoma, a common form of skin cancer, and mutated GRM3 
increased cellular migration23. The upregulation of GRM3 is considered to lead to the inactivation of cAMP sig-
naling followed by the stimulation of cellular migration24. Compared to BMD cells, the mRNA levels of several 
PDEs, including PDE8B, PDE4B, and PDE5A, were higher in TMD cells. The elevated expression of these PDEs 
in TMD cells is consistent with the reduction of cAMP signaling and promotion of cellular migration. These 
PDEs were downregulated in the presence of GRM3 siRNA, further supporting the notion that GRM3 is involved 
in the regulation of cAMP signaling via PDEs.
Among mitogen-activated protein kinases that are known to regulate cell migration25, the phosphorylation 
level of p38 (p-p38) was altered in two cell lines as well as by RNA silencing with GRM3 siRNA. Compared to 
TMD cells, less-migratory BMD cells showed a lower level of p-p38. Also, treatment of TMD cells with GRM3 
siRNA lowered the level of p-p38. The result indicates that BMD’s reduction in cell migration is in part caused 
by the nonsense mutation of GRM3. Since treatment of TMD cells with GRM3 siRNA did not alter the level of 
S100A4, GRM3 does not directly regulate S100A4.
Cell migration and invasion also depend on interaction with the microenvironment. Four integrin β subunit 
genes were upregulated in TMD cells. Integrin β subunits are instrumental in facilitating feedback to cells about 
the surrounding mechanical environment. Their increased activity in tumor cells enhance their invasiveness26, 
and the elevated expression of ITGB3, ITGB4, ITGB5, and ITGB8 in TMD cells is consistent with their migratory 
capabilities. MMPs also alter the microenvironment by remodeling extracellular matrix, and the role of MMP2 
and MMP9 in tumor migration is well documented27. While the activity of MMP9 was elevated in TMD cells, 
we also observed significant upregulation of MMP1 in BMD cells. Since BMD cells are harvested from the site of 
metastasis in bone, they may activate collagenases such as MMP1 for remodeling the novel microenvironment28.
symbol description allele freq. base change a.a. change
GRM3 glutamate receptor, metabotropic 3 1.00 G/T E/stop
BHMT2 betaine-homocysteine S-methyltransferase 2 0.29 G/T E/stop
REXO1L1P REX1, RNA exonuclease 1 homolog-like 1 0.24 G/A Q/stop
FCGR1A Fc fragment of IgG Ia, receptor (CD64) 0.22 C/T Q/stop
ANKRD20A4 ankyrin repeat domain 20 A4 0.70 A/G S/G
ANKRD20A1 ankyrin repeat domain 20 A1 0.69 T/C S/P
DMBT1 deleted in malignant brain tumors 1 0.69 A/G H/R
ANKRD20A3 ankyrin repeat domain 20 A3 0.66 A/G S/P
ANKRD20A3 ankyrin repeat domain 20 A3 0.62 C/A S/I
ANKRD20A1 ankyrin repeat domain 20 A1 0.58 T/C M/T
ANKRD20A1 ankyrin repeat domain 20 A1 0.55 A/G S/G
ANKRD20A4 ankyrin repeat domain 20 A4 0.55 C/T R/C
GGT2 gamma-glutamyltransferase 2 0.53 C/T A/T
PLA2G2E phospholipase A2, group IIE 0.51 G/A R/C
LRRC37A2 leucine rich repeat containing 37, member A2 0.51 T/G L/V
ZNF705D zinc finger protein 705D 0.48 G/A G/R
NUTM2D NUT family member 2D 0.47 T/C W/R
RASIP1 Ras interacting protein 1 0.47 C/G A/P
SPATA31A6 SPATA31 subfamily A, member 6 0.46 C/T A/T
KRTAP4–12 keratin associated protein 4–12 0.46 G/C S/R
TAF4 TAF4 RNA polymerase II 0.46 C/A A/S
CTAGE4 CTAGE 4 0.46 A/G I/V
NPIPA5 nuclear pore complex interacting protein A5 0.45 A/G V/A
USH2A Usher syndrome 2 A 0.43 C/G V/L
PLCB2 phospholipase C, beta 2 0.42 C/T M/I
Table 1. Mutations in BMD cells.
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A microfluidic experiment using a tapered channel demonstrated that TMD cells were less rigid and more 
deformable than BMD cells. Accumulating evidence indicates that cell rigidity differs depending on the devel-
opmental stage of tumor cells, and metastatic cells tend to be more deformable and softer than non-metastatic 
cells29, 30. It has been shown, for instance, that MDA-MB-231 cells are softer than MCF-7 non-tumor epithelial 
Figure 4. Effects of GRM3 in the spheroid shape. (A) Mutation of GRM3 in BMD cells. (B) Partial silencing of 
GRM3 using RNA interference. Full length blots are presented in Supplementary Figure 3. (C) Effects of GRM3 
siRNA in the spheroid composed of TMD cells and MC3T3 cells. (D–F) Changes in the spheroid parameters 
by treatment with GRM3 siRNA in TMD/MC co-cultured cells. (G) Protein levels of S100A4, p-ERK, ERK, 
p-p38, p-38, p-Paxillin, p-Akt, Akt, p-JNK, JNK, β-catenin, and β-actin. Full length blots are presented in 
Supplementary Figure 4. (H) Effects of spaglumic acid treatment on the area of TMD and MC3T3 co-culture 
spheroids.
www.nature.com/scientificreports/
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cells31. Using a microfluidic channel that was connected to a hydrodynamic syringe pump, the passing time of 
TMD cells in a narrowly tapered channel was characterized with and without Paclitaxel pretreatment. The longer 
passing time for Paclitaxel-treated cells indicates that Paclitaxel makes cells less deformable and/or more adhesive 
to the microfluidic channel. An understanding of the dynamical cellular process in this microfluidic assay may 
contribute to evaluating the role of chemotherapeutic agents for preventing metastasis through blood circulation. 
Furthermore, Paclitaxel’s inhibition of S100A4, potentially through modulating myosin assembly, may also help 
prevent migration and metastasis.
The phenotypic differences between tumor-derived (TMD) and bone metastasis-derived (BMD) cells may be 
explained by the cooperativity model of metastasis through a cluster of heterogeneous tumor cells. Accordingly, 
the cluster is composed of the mesenchymal-like TMD cells and the epithelial-like BMD cells. TMD cells are 
Figure 5. Elevated expression of integrin, MMP9, and phosphodiesterase (PDE) in TMD cells. (A,B) Elevated 
integrin β subunits (B3, B4, B5, and B8) in TMD cells. (C,D) Messenger RNA level and activity of MMP9. 
(E) Comparison of the mRNA levels of the selected PDEs (8B, 1C, 4B, and 5A) in TMD and BMD cells. (F) 
Reduction in the mRNA levels of the selected PDEs in TMD cells by GRM3 siRNA. NC = non-specific control 
siRNA.
www.nature.com/scientificreports/
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the drivers for migration away from the primary tumor site and invasion into the blood stream together with 
BMD cells. At the site of metastasis in a bone microenvironment, BMD cells have a higher chance of integration 
with surrounding bone cells because of their less migratory and stronger adherent phenotype. While S100A4 
and GRM3 are two regulators that are associated with migration of tumor cells20, 23, decreased stiffness of TMD 
cells are consistent with their ability to invade and provide a path for epithelial-like BMD cells to the bone 
microenvironment.
There were several limitations to this study. We employed triple negative breast cancer cell lines instead of 
other types. Since bone metastasis is more frequent for ER-positive breast cancer cells, it is important to evaluate 
Figure 6. Effects of Paclitaxel in cellular motility, S100A4 expression, and passing behavior in a microfluidic 
channel. The single and double asterisks indicate p < 0.05 and p < 0.01, respectively. (A,B) Reduction in 
2-dimensional cellular motility by 10 µM Paclitaxel in TMD cells and BMD cells. (C) Reduction in S100A4 
protein level by 10 µM Paclitaxel in TMD cells. (D) Microfluidic channel for evaluating passing behaviors of 
TMD cells with and without Paclitaxel treatment. The arrow head indicates individual TMD cells in the channel. 
(E) Histogram of a passing time in a 300-µm channel for TMD cells (control) and Paclitaxel-treated TMD cells. 
(F) Longer passing time for Paclitaxel-treated TMD cells than control cells.
www.nature.com/scientificreports/
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mRNA profiles and DNA variants in ER-positive cells32. TMD and BMD cells are likely to be composed of a vari-
ety of sub-populations with their unique DNA variants, and cell abilities of migration and invasion are dependent 
on other culture conditions besides 2- and 3-dimensional culture environments33. Finally, while BMD cells are 
reported to be linked to cytokine/hematopoietic stem cell signaling9, any role of BMD and TMD cells as cancer 
stem cells is yet to be elucidated. In summary, by analyzing differential mRNA expression profiles and exon vari-
ations in TMD/BMD cells, this study demonstrated that S100A4 and GRM3 induced TMD’s higher ability of cell 
motility and invasion, as well as a rougher, less circular surface in spheroids. Whether S100A4 and GRM3 can be 
utilized as therapeutic targets for bone metastasis from breast cancer is worth further pursuit.
Materials and Methods
Cell culture. MDA-MB-231 human breast cancer cells, TMD cells, and BMD cells, were grown in DMEM 
(Corning, Inc., Corning, NY, USA) and MC3T3 osteoblast-like cells were grown in αMEM (Gibco, Carlsbad, CA, 
USA). The culture media contained 10% fetal bovine serum (FBS) and antibiotics (50 units/ml penicillin, and 
50 µg/ml streptomycin; Life Technologies, Grand Island, NY, USA). Cells were maintained at 37 °C and 5% CO2 
in a humidified incubator. To measure the gene and protein expression levels in 2D, cells were seeded on 6-cm 
tissue culture dishes (Corning). To measure expression in three dimensions, 105 cells were seeded in 100 µL cul-
ture media in U-bottom low-adhesion 96-well plates (S-Bio, Hudson, NH, USA), combining 6 wells per sample. 
After 48 h, cells were harvested.
Motility assay and invasion assay. To evaluate 2-dimensional motility, a wound healing scratch motil-
ity assay was carried out. Cells were seeded in 6-well tissue culture plates, and on the next day, scratching was 
performed using a plastic pipette tip. The areas newly occupied with cells in the scratched zone were deter-
mined 10 h or 24 h after scratching using images obtained by a microscope quantified with Image J. To exam-
ine 3-dimensional invasion, Matrigel (100 µg/ml; BD Biosciences) was coated to the polyethylene terephthalate 
membrane (8-µm pore size, 23.1 mm in diameter, Falcon) and left to polymerize overnight. Cells (~5 × 105/
well) were seeded in the upper chamber. After 24 h, the cells on the membrane surface were stained with Giemsa 
(Sigma-Aldrich) and the number of cells was counted under the microscope.
MMP9 activity assay. MMP9 activity in cell culture media was determined per manufacturer’s instruc-
tions using an activity assay kit with a fluorescent substrate cleaved by MMP-9 (SensoLyte 520 MMP9 Assay Kit, 
AnaSpec, Inc., Fremont, CA, USA). GM1489 (MMP1 inhibitor; EMD Millipore, Billerica, MA, USA) was sup-
plemented to the reaction mixture at 0.1–10 μM to suppress nonspecific degradation of the substrate by MMP-1.
Spheroid co-culture assay. To induce spheroid formation, TMD cells or BMD cells were cultured in a 
U-bottom low-adhesion 96-well plate in the presence and absence of MC3T3 cells (cell ratio 2:1, MC3T3:cancer 
cells; total cells 1 × 105/well) in αMEM culture media34. After 48 h, microscope images were taken of the sphe-
roid to be analyzed with ImageJ. A threshold was applied and the spheroid area was identified with the “Analyze 
Particle” function. Area and circularity of the identified object were measured directly with ImageJ. Roughness 
was calculated by fitting an ellipse to the spheroid and adding the areas of the spheroid outside the ellipse and the 
areas of the ellipse not within the spheroid.
cDNA microarray and principal component analysis (PCA). Using cDNA microarrays (Human 
Gene 2.0 ST, Affymetrix), genome-wide mRNA expression profiles were determined using RNA isolated with an 
RNeasy Plus Mini kit (Qiagen, Germantown, MD, USA) from 9 samples, including 3 samples each from 3 groups 
of cells (MDA-MB-231 parental cells, TMD cells, and BMD cells). In PCA, nine samples in three groups were 
positioned in the plane of the first and second principal component (PC) axes. In the plane defined by the first 
and second PC axes, we selected a specific axis (metastasis axis), which was parallel to the line connecting TMD 
cells to BMD cells. This metastasis axis was ~20° rotated from the second PC axis. Among S100 calcium binding 
proteins that are often involved in cancer metastasis, S100A4 gene was mapped at an extremum of the metastasis 
axis. Thus, its role for migratory behaviors of TMD/BMD cells was further evaluated.
Real-time qPCR and Western blot analysis. Total RNA was extracted using an RNeasy Plus mini kit 
(Qiagen, Germantown, MD, USA) and reverse transcription was conducted with high capacity cDNA reverse 
transcription kits (Applied Biosystems, Carlsbad, CA, USA) to produce cDNA. Real-time qPCR was performed 
using Power SYBR green PCR master mix kits (Applied Biosystems) with PCR primers listed in Table 2. In 
Western blot analysis, cells were lysed in a radio-immunoprecipitation assay (RIPA) buffer. Isolated proteins 
were fractionated using 10% SDS gels and electro-transferred to polyvinylidene difluoride membranes (Millipore, 
Billerica, MA, USA). We used antibodies against S100A4, p-ERK, ERK, p-p38, p38, p-AKT, AKT, p-JNK, JNK, 
p-Paxillin, β-catenin (Cell Signaling), GRM3 (Abcam), and β-actin (Sigma). Protein levels were assayed using a 
SuperSignal west femto maximum sensitivity substrate (Thermo Scientific, Waltham, MA, USA).
Knockdown of S100A4 and GRM3 by siRNA. Cells were treated with siRNA specific to S100A4 (5′- 
GCA UCG CCA UGA UGU GUA A -3′) (Life Technologies) or GRM3 (Dharmacon SMARTpool siRNA library). 
As a nonspecific control, a negative siRNA (Silencer Select #1, Life Technologies) was used. Cells were transiently 
transfected with siRNA in Opti-MEM I medium with Lipofectamine RNAiMAX (Life Technologies). Six hours 
later, the medium was replaced by regular culture medium. The efficiency of silencing was assessed with immu-
noblotting 48 h after transfection.
DNA mutation analysis. Genomic DNA was extracted from BMD cells and TMD cells using QIAamp 
DNA mini kit (Qiagen). Exon capture analysis was conducted using the Complete Genomics platform (BGI, 
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Cambridge, MA, USA). After receiving aligned sequences, high quality reads were filtered with samtools35, var-
iants occurring in the BMD cells but not TMD cells were identified using MuTect (Broad Institute)36 and anno-
tated using Variant Effect Predictor (Ensembl)37, followed by a manual assessment of their quality. We identified 
highly occurring variants, filtering by stop-gain and exonic missense mutations.
TMD cells in a microfluidic channel. In a parallel array (20 mm in length and 1.23 mm in width), 
hydro-dynamically driven microfluidic channels, 300 µm in length, were designed and fabricated. Each channel 
has an inlet of 30 µm in width and an outlet of 5, 10, or 15 µm in width. TMD cells were pre-cultured in the pres-
ence and absence of 10 µM Paclitaxel for 24 h, and they were detached from the culture dish by trypsin prior to a 
flow experiment. In the microfluidic channel with 5 µm outlet, culture medium was introduced at a flow rate of 
5 µl/min, and the passage time of individual cells from channel entry to exit was determined.
Statistical analysis. Three or four independent experiments were conducted and data were expressed as 
mean ± S.D. Statistical significance was evaluated at p < 0.05, and the single and double asterisks in the figures 
indicate p < 0.05 and p < 0.01, respectively.
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